Insider Selling: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO Sells $33,647.85 in Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO Adam S. Mostafa sold 74,773 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

X4 Pharmaceuticals Price Performance

XFOR opened at $0.74 on Thursday. X4 Pharmaceuticals, Inc. has a twelve month low of $0.26 and a twelve month high of $1.60. The company has a market capitalization of $125.39 million, a price-to-earnings ratio of -8.17 and a beta of 0.14. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The firm has a 50-day moving average price of $0.55 and a 200-day moving average price of $0.61.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. State Street Corp grew its stake in X4 Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after acquiring an additional 189,105 shares in the last quarter. Ensign Peak Advisors Inc increased its stake in X4 Pharmaceuticals by 4.6% in the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after acquiring an additional 111,032 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of X4 Pharmaceuticals by 15.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock valued at $418,000 after purchasing an additional 81,968 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of X4 Pharmaceuticals during the third quarter worth approximately $340,000. Finally, AQR Capital Management LLC raised its position in X4 Pharmaceuticals by 1,080.3% in the 2nd quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after purchasing an additional 388,115 shares during the period. 72.03% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Stifel Nicolaus decreased their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $1.50 price target on shares of X4 Pharmaceuticals in a report on Tuesday, January 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.